person · Reporting owner
GROENHUYSEN WILHELMUS CM
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | June 28, 2024 | August 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 28, 2024 · Filed August 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 252,290 |
Reported balance
After 2024-06-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-28 · Grant · Acquired 1,055 · Balance 252,290 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 2,133 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.10 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.75 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.00 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.50 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.00 · Expires 2027-10-12 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-21 · Disposition to issuer · Disposed 1,925 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,400 | $80.92 | $356,061.20 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,279 F4 · price: On September 9, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 4,400 shares in multiple trades at prices ranging from $80.55 to $81.49. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,643 | $79.73 | $130,989.82 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,679 F3 · price: On September 9, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,643 shares in multiple trades at prices ranging from $79.20 to $80.08. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,857 | $78.70 | $539,673.33 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,322 F2 · price: On September 9, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 6,857 shares in multiple trades at prices ranging from $78.18 to $79.17. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $3.44 | $86,000.00 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:23 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 454 | $27.81 | $12,626.65 |
DisclosureSEC source: 0001209191-19-041558 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2019 through June 30, 2019. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2019. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 10:50 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 14,439 | $6.60 Strike: $6.60 | $95,297.40 |
DisclosureSEC source: 0001494650-19-000058 · wf-form4_156017819796955.xml · derivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,439 Underlying: Common Stock · 14,439 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 6, 2020 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2020 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028881 · doc4.xml · derivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: Options to buy 20,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Groenhuysen has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 36,650 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028881 · doc4.xml · derivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,650 Underlying: Ordinary Shares · 36,650 shares Expires 2029-05-08 F1 · derivative.exercise_date: Options to buy 36,650 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Groenhuysen has been continuously employed by the Company through May 8, 2022. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:25 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 37,461 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001209191-19-021327 · doc4.xml · derivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,461 Underlying: Ordinary Shares · 37,461 shares Expires 2029-03-21 F2 · derivative.exercise_date: Options to buy 37,461 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:25 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 20,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021327 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,725 F1 · shares: Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 31,234 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · derivative · entry 16 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,663 Underlying: Ordinary Shares · 31,234 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 31,234 | $53.40 | $1,668,020.54 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 13 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,264 F11 · price: On March 5, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 31,234 shares in multiple trades at prices ranging from $53.35 to $53.56. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 31,234 | $3.44 | $107,444.96 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 12 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 40,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · derivative · entry 15 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,897 Underlying: Ordinary Shares · 40,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 18,766 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · derivative · entry 14 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,897 Underlying: Ordinary Shares · 18,766 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,342 | $56.50 | $245,336.03 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 11 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,264 F10 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 4,342 shares in multiple trades at prices ranging from $56.39 to $56.61. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,800 | $55.95 | $156,654.40 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,606 F9 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,800 shares in multiple trades at prices ranging from $55.35 to $56.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,800 | $54.54 | $152,720.40 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,406 F8 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,800 shares in multiple trades at prices ranging from $54.35 to $55.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,207 | $53.82 | $226,403.91 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,206 F7 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 4,207 shares in multiple trades at prices ranging from $53.35 to $54.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 25,851 | $52.90 | $1,367,595.45 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,413 F6 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 25,851 shares in multiple trades at prices ranging from $52.34 to $53.32. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 40,000 | $3.44 | $137,600.00 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,222 | $56.52 | $295,152.66 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,264 F5 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 5,222 shares in multiple trades at prices ranging from $56.35 to $56.63. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,748 | $56.04 | $266,054.18 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,486 F4 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 4,748 shares in multiple trades at prices ranging from $55.35 to $56.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,400 | $54.56 | $185,497.20 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,234 F3 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,400 shares in multiple trades at prices ranging from $54.35 to $55.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,396 | $53.91 | $290,876.78 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,634 F2 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 5,396 shares in multiple trades at prices ranging from $53.35 to $54.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 18,766 | $3.44 | $64,555.04 |
DisclosureSEC source: 0001209191-19-017332 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 21:36 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,288 | $53.68 | $176,499.84 |
DisclosureSEC source: 0001209191-19-015004 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,264 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:36 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 7,717 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015004 · doc4.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,431 Underlying: Ordinary Shares · 7,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:36 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,717 | $52.90 | $408,229.30 |
DisclosureSEC source: 0001209191-19-015004 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 22:58 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 18,647 | $53.63 | $1,000,001.32 |
DisclosureSEC source: 0001209191-19-013681 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,835 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:58 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 43,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013681 · doc4.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,333 Underlying: Ordinary Shares · 43,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:58 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 43,333 | $53.38 | $2,313,115.54 |
DisclosureSEC source: 0001209191-19-013681 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 35,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-005510 · doc4.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,663 Underlying: Ordinary Shares · 35,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 35,000 | $49.20 | $1,722,000.00 |
DisclosureSEC source: 0001209191-19-005510 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,149 F2 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 35,000 | $3.44 | $120,400.00 |
DisclosureSEC source: 0001209191-19-005510 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 35,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-005318 · doc4.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,663 Underlying: Ordinary Shares · 35,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 35,000 | $47.35 | $1,657,250.00 |
DisclosureSEC source: 0001209191-19-005318 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,149 F2 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 35,000 | $3.44 | $120,400.00 |
DisclosureSEC source: 0001209191-19-005318 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 30,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-004784 · doc4.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,663 Underlying: Ordinary Shares · 30,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 30,000 | $45.90 | $1,376,910.00 |
DisclosureSEC source: 0001209191-19-004784 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,149 F2 · price: On January 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 30,000 shares in multiple trades at prices ranging from $45.85 to $45.92. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 22:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 30,000 | $3.44 | $103,200.00 |
DisclosureSEC source: 0001209191-19-004784 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 30,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-003939 · doc4.xml · derivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,663 Underlying: Ordinary Shares · 30,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 30,000 | $44.20 | $1,326,000.00 |
DisclosureSEC source: 0001209191-19-003939 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,149 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 30,000 | $3.44 | $103,200.00 |
DisclosureSEC source: 0001209191-19-003939 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 11, 2019 Filed Jan 14, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 30,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-003544 · doc4.xml · derivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,663 Underlying: Ordinary Shares · 30,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| January 11, 2019 Filed Jan 14, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 30,000 | $42.35 | $1,270,500.00 |
DisclosureSEC source: 0001209191-19-003544 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,149 F3 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 11, 2019 Filed Jan 14, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 30,000 | $3.44 | $103,200.00 |
DisclosureSEC source: 0001209191-19-003544 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 10, 2019 Filed Jan 14, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 25 | $27.20 | $680.00 |
DisclosureSEC source: 0001209191-19-003544 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,149 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2018 through December 31, 2018. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 2, 2018. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,973 | $40.03 | $399,203.23 |
DisclosureSEC source: 0001209191-18-048681 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,124 F2 · price: On August 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 9,973 shares in multiple trades at prices ranging from $40.00 to $40.20. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $40.05 | $4,005.00 |
DisclosureSEC source: 0001209191-18-048681 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,097 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.